ASH 2020

Complete Coverage

Prognostic Biomarker Testing in CLL/SLL Remains Low

Hospitalization Burden of Patients With Multiple Myeloma

Liso-Cel Plus Ibrutinib Demonstrated Efficacy in R/R CLL/SLL

Bispecific CAR-T Therapy Found to Have Promising Efficacy in Older Patients With R/R B-Cell NHL

Fixed Duration Ibrutinib-Venetoclax for CLL Resulted in High Rate of Undetectable MRD

Hematopoietic Stem Cell Transplantation May Not Reduce Renal Function in Sickle Cell Disease

Azacitidine vs Decitabine in Unfit, Newly Diagnosed Acute Myeloid Leukemia

Decitabine With Venetoclax as Salvage Therapy in R/R Acute Myeloid Leukemia

BCMA-Directed CAR-T Therapy Shows Clinical Activity in Multiple Myeloma

Duvelisib Had Consistent Response Rates in R/R Peripheral T-Cell Lymphoma